Careers

Birth of the term 'exosome' through the discovery of shed vesicles from cells.

First description by Harding et al, of maturing reticulocytes releasing vesicles into the extracellular space

Landmark discovery by Raposo et al, describing vesicle-meditated transfer of antigens.

First of several discoveries describing the transfer of mRNA and miRNA by Evs.

One of the most cited articles in the journal's history, showing that engineered exosomes are capable of delivering siRNA to the brain.

Founded in Oxford, by Dr. Per Lundin, Professor Matthew Wood, and Dr. Samir El Andaloussi.  The company was spun out from Oxford University and the Karolinska Institute in Sweden.

£10 million raised from Oxford Sciences Innovation.

Evox entered into two R&D pharma collaborations with global pharmaceutical companies.

£35.5 million raised, bringing new investors into Evox Therapeutics. Redmile Group, Google Ventures, Cowen Healthcare Ventures, Panacea Ventures, and Borealis Ventures. 

Evox moved into the Medawar building.

Takeda and Evox Therapeutics sign multi-target Rare Disease collaboration.

Lilly and Evox Therapeutics announce a multi-target RNAi and antisense research collaboration and license agreement.